Kairos Pharma, Ltd. (NYSE American: KAPA) announced it will host a virtual Key Opinion Leader (KOL) event on Thursday, September 18th, to discuss diverse perspectives on the interim efficacy results from its Phase 2 trial of ENV105. The trial is evaluating ENV105 in treating advanced prostate cancer patients.
The event is set to feature principal investigators from the trial, who will provide insights into the data. This predetermined efficacy analysis occurs four months after the start of combination therapy of ENV105 and apalutamide in the last safety lead-in patient.
CEO Dr. John Yu stated that the company hopes to lay out the primary benefits of its compound and clearly demonstrate the clinical need filled by ENV105. The interim safety analysis, announced in July, showed ENV105 was well tolerated with no Grade 3 or 4 toxicities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.